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OBJECTIVES We sought to study the role of IKACh in atrial fibrillation (AF) and the potential
electrophysiologic effects of a specific IKACh antagonist.
BACKGROUND IKACh mediates much of the cardiac responses to vagal stimulation. Vagal stimulation
predisposes to AF, but the specific role of IKACh in the generation of AF and the
electrophysiologic effects of specific IKACh blockade have not been studied.
METHODS Adult wild-type (WT) and IKACh-deficient knockout (KO) mice were studied in the absence
and presence of the muscarinic receptor agonist carbachol. The electrophysiologic features of
KO mice were compared with those of WT mice to assess the potential effects of a specific
IKACh antagonist.
RESULTS Atrial fibrillation lasting for a mean of 5.7 6 11 min was initiated in 10 of 14 WT mice in
the presence of carbachol, but not in the absence of carbachol. Atrial arrhythmia could not be
induced in KO mice. Ventricular tachyarrhythmia could not be induced in either type of
mouse. Sinus node recovery times after carbachol and sinus cycle lengths were shorter and
ventricular effective refractory periods were greater in KO mice than in WT mice. There was
no significant difference between KO and WT mice in AV node function.
CONCLUSIONS Activation of IKACh predisposed to AF and lack of IKACh prevented AF. It is likely that
IKACh plays a crucial role in the generation of AF in mice. Specific IKACh blockers might be
useful for the treatment of AF without significant adverse effects on the atrioventricular node
or the ventricles. (J Am Coll Cardiol 2001;37:2136–43) © 2001 by the American College of
Cardiology
The parasympathetic nervous system acts through the vagus
nerve to regulate the heart rate and the conduction proper-
ties of atrial, atrioventricular (AV) nodal and ventricular
tissue. In animal models, parasympathetic stimulation has
been shown to predispose the atria to fibrillation, and vagal
denervation has prevented the induction of atrial fibrillation
(AF) (1,2). Parasympathetic stimulation leads to a release of
acetylcholine from the vagus nerve. Acetylcholine binds
muscarinic receptors, triggering a heterotrimeric G-protein
cascade that results in activation of the muscarinic-gated
potassium channel IKACh, as well as modulation of a host of
other ion channels (3,4). In mammals, IKACh is found in the
cardiac conductive tissue, sinoatrial (SA) node, atria, AV
node and cardiac Purkinje fibers (5). In some species, IKACh
has also been reported to be present in ventricular myocytes
(6,7). Given the lack of specific pharmacologic antagonists
for IKACh, it has been difficult to evaluate its relative
contribution to key aspects of normal cardiac function, its
role in the pathogenesis of cardiac arrhythmias and the
cardiac electrophysiologic effects of specific IKACh blockade.
Cardiac IKACh is comprised of two homologous pro-
teins—GIRK1 and GIRK4 (8–10). In cell expression sys-
tems, both GIRK1 and GIRK4 are required to recapitulate
the key features of IKACh conductance (10,11). In the
absence of GIRK4, GIRK1 does not form a functional ion
channel, due to its inability to achieve cell surface expression
(12–14). Given these observations, we reasoned that abla-
tion of GIRK4 would result in the functional elimination of
IKACh. Previously, we described the targeted ablation of the
mouse GIRK4 gene and preliminarily characterized the
cardiac phenotype of this mouse line (15). Mice lacking
GIRK4 (IKACh-deficient knockout [KO] mice) are viable
and appear normal. Molecular and electrophysiologic anal-
yses of atrial tissue isolated from the GIRK4 KO mice
demonstrated complete absence of the GIRK4 protein and
IKACh conductance, respectively. Although rest heart rates
and PR intervals of KO and wild-type (WT) mice did not
differ significantly, pharmacologic stimulation of vagal ac-
tivity had a significantly decreased negative chronotropic
effect in KO mice compared with WT mice. This finding
indicates that IKACh plays a major role in the parasympa-
thetic regulation of heart rate. In addition, beat-to-beat
fluctuation in heart rate was significantly diminished in KO
mice compared with WT control mice, suggesting that
IKACh modulation constitutes the primary mode of heart
rate control over short time frames (,2 s).
In this study, we tested the hypothesis that IKACh is
essential for the profibrillatory effects of vagal stimulation on
the atria. Furthermore, we sought to study the potential
effects of a specific IKACh antagonist by comparing the
cardiac electrophysiologic features of KO and WT mice.
From the *Department of Cardiology, Westmead Hospital, Sydney, Australia;
†Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota;
and ‡Children’s Hospital and Harvard Medical School, Boston, Massachusetts. Dr.
Kovoor was supported by a grant from the Australian Heart Foundation. Dr.
Clapham was supported by the Howard Hughes Medical Institute and a grant from
the National Institutes of Health, NHLBI 54873 Bethesda, Maryland. Dr. Berul was
supported by a grant from the National Institutes of Health K08-03607; Dr.
Gauvreau is supported in part by the Kobren Fund.
Manuscript received June 22, 2000; revised manuscript received February 27, 2001,
accepted March 22, 2001.
Journal of the American College of Cardiology Vol. 37, No. 8, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01304-3
We used intracardiac pacing and recording catheters to
measure several variables of SA nodal, atrial, AV nodal and
ventricular function in WT and KO mice under rest conditions
and after administration of the muscarinic agonist carbachol.
METHODS
GIRK4 knockout mice. The generation of GIRK4 KO
mice and their preliminary molecular and functional char-
acterization have been described previously (15). The
GIRK4 null allele has since been back-crossed through
seven generations onto the C57BL6/J mouse strain. For the
experiments described subsequently, F2 GIRK4 KO sib-
lings were mated to produce litters consisting entirely of F3
GIRK4 KO mice. Fourteen 12-week-old GIRK4 KO mice
were used for the experiments. Measurements could not be
obtained in three of the GIRK4 KO mice because of
technical problems with the recording equipment (n 5 2)
and cardiac perforation (n 5 1). Fourteen gender- and
age-matched WT C57BL6/J mice (Jackson Laboratories,
Bar Harbor, Maine) were used as control animals.
Electrophysiologic studies. Analysis of mouse cardiac
electrophysiologic variables was performed in anesthetized
mice by using a modification of previously described meth-
ods (16,17). Briefly, the mice were anesthetized with intra-
peritoneal administration of pentobarbital (0.13 mg/g body
weight). The surface six-lead electrocardiogram (ECG) was
recorded from subcutaneous 25-gauge electrodes in each
limb. A 2F octapolar catheter (CIBer Mouse EP Catheter,
NuMed Inc., Hopkinton, New York) was introduced
through the right internal jugular vein into the right
ventricle. Each electrode was 0.5 mm in length, with a
0.5-mm interelectrode distance. The distal electrodes were
used for sensing and pacing of the right ventricle, and the
proximal electrodes were used for sensing and pacing the
right atrium. The ECG channels were amplified (0.1
mV/cm) and filtered between 0.5 and 250 Hz. The ECG
variables were calculated according to standard criteria.
High-fidelity intracardiac electrogram signals were filtered
between 5 and 400 Hz and acquired at a sampling rate of
1,000 Hz.
Sinus node function was evaluated by measuring the rest
sinus cycle length and the sinus node recovery time. Sinus
node function was assessed by pacing the atrium continu-
ously for 15 s at cycle lengths of 200 and 150 ms and
measuring the duration of the return cycle. To adjust for the
sinus cycle length, the sinus node recovery time was also
expressed as a percentage of the sinus cycle length.
Anterograde AV nodal function was assessed from the
AV interval and during incremental right atrial pacing from
the sinus cycle length down to 50 ms. The minimal cycle
length required to maintain 1:1 AV conduction, the
Wenckebach paced cycle length and the maximal paced
cycle length causing 2:1 AV block were determined. Pro-
grammed right atrial stimulation was performed at a cycle
length of 150 ms to determine the AV effective refractory
period. Retrograde conduction along the AV node and His
Purkinje system was assessed during incremental right
ventricular pacing from the sinus cycle length down to
50 ms. The minimal cycle length required to maintain 1:1
ventriculo-atrial conduction, the ventriculo-atrial Wenck-
ebach paced cycle length and the maximal paced cycle
length causing 2:1 ventriculo-atrial block were determined.
Programmed right atrial stimulation was performed at a
cycle length of 150 ms to determine the AV effective
refractory period. Double and triple extrastimulation tech-
niques down to a minimal coupling interval of 10 ms were
performed in an attempt to induce atrial arrhythmias. Right
atrial burst pacing at rates of 40 to 80 ms was also performed
to induce atrial arrhythmias.
Programmed right ventricular stimulation was performed
at a cycle length of 150 ms to determine the ventricular
effective refractory period. Double and triple extrastimula-
tion techniques down to a minimal coupling interval of
40 ms were performed in an attempt to induce ventricular
arrhythmias. Right ventricular burst pacing at rates of 40 to
80 ms was also performed to induce ventricular arrhythmias
(16).
After all baseline electrophysiologic variables were re-
corded, carbachol was administered intraperitoneally at a
dose of 50 ng/g. The entire protocol was repeated 5 min
after administration of carbachol to assess muscarinic mod-
ulation of electrophysiologic variables (18).
Isolation of ribonucleic acid (RNA) and reverse tran-
scription polymerase chain reaction (PCR). Total RNA
was isolated from the atrial appendages and ventricular
apices of WT adult mouse hearts using Trizol reagent,
according to the manufacturer’s instructions (Gibco BRL,
Rockville, Maryland). Negative control RNA was obtained
from NIH-3T3 cells. One microgram of total RNA was
reverse transcribed using oligo(dT) primers, with the Su-
perScript First-Strand complementary deoxyribonucleic
acid Synthesis kit (Gibco BRL). Ten percent of the reaction
product was amplified by PCR using GIRK1-, GIRK4- or
myosin light chain (MLC)-2a–specific primers. The PCR
primers were designed to hybridize to GIRK4 or the
MLC-2a coding sequence on either side of an intron. The
PCR cycling variables are available on request. The PCR
products were visualized by gel electrophoresis (2% agarose)
followed by ethidium bromide staining.
Abbreviations and Acronyms
AF 5 atrial fibrillation
AV 5 atrioventricular
ECG 5 electrocardiogram or electrocardiographic
KO 5 IKACh-deficient knockout (mice)
MLC 5 myosin light chain
PCR 5 polymerase chain reaction
RNA 5 ribonucleic acid
SA 5 sinoatrial
WT 5 wild-type (mice)
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Statistical analysis. Cardiac electrophysiologic variables
were compared for WT and KO mice before and after
carbachol administration by using the two-tailed Student t
test and two-way analysis of variance with repeated mea-
sures on one factor, where appropriate. Interaction terms
were used to evaluate whether the effect of carbachol
differed between the genotype groups. Data are presented as
the mean value 6 SEM. Statistical significance was defined
as p , 0.05.
RESULTS
Arrhythmia inducibility. In the absence of carbachol ad-
ministration, no atrial or ventricular arrhythmias could be
induced with programmed stimulation or with burst
pacing in either WT or KO mice. After carbachol admin-
istration, AF lasting for a mean of 5.7 6 11 min was
induced in 10 of 14 WT mice (Fig. 1). In contrast, KO mice
remained uninducible when treated with carbachol. In the
WT mice, AF could be repeatedly induced using burst
atrial pacing, programmed atrial stimulation, burst ventric-
ular pacing or programmed ventricular stimulation. In
susceptible mice, AF could be induced 3.1 6 1.9 times. In
one mouse, atrial arrhythmia began as a more organized-
appearing tachycardia (i.e., atrial flutter), which subse-
quently degenerated into AF. Atropine (40 mg intraperito-
neally) was administered in one mouse after 35 min of
AF, and in another mouse after 66 s of AF. In these
instances, AF abruptly terminated after 2 min and 45 s,
respectively. Re-induction of AF was attempted after
atropine administration in three mice in which AF had
been induced multiple times; AF could not be re-induced in
these mice. Ventricular tachyarrhythmia could not be in-
duced in mice of either genotype under any tested condi-
tion.
Cardiac electrophysiologic variables. The cardiac electro-
physiologic variables in WT and KO mice measured at
baseline and after carbachol administration are summarized
in Table 1. The main differences between KO and WT mice
at baseline were in the sinus cycle length and ventricular
effective refractory period. Mice lacking IKACh (i.e., KO
mice) had faster rest heart rates (shorter sinus cycle lengths)
than WT mice under these experimental conditions. Fur-
thermore, the ventricular effective refractory period was
longer in KO mice than in WT mice. There was no
significant difference in any other measured variable.
After carbachol administration, the differences in the
sinus cycle length and ventricular effective refractory period
between the KO and WT mice persisted, without an
interaction effect (Table 1). In addition, the KO mice
displayed significantly shorter sinus node recovery times
after pacing at the 150-ms cycle length (Fig. 2). After
pacing at a cycle length of 200 ms, the sinus node recovery
time was likewise shorter in the KO mice than in the WT
mice, although at the longer cycle length, the difference
between the groups was evident only after adjusting for the
post-carbachol sinus cycle length.
Changes between the baseline and post-carbachol elec-
trophysiologic variables were compared between the geno-
types (Table 1). The WT mice exhibited a greater change
from baseline in sinus node recovery time, as well as a
greater change in the AV interval after carbachol adminis-
tration, compared with KO mice. We found it difficult to
compare the atrial effective refractory periods of WT and
KO mice because of the very small values and difficulty in
differentiating atrial capture from stimulus artifact.
IKACh subunit expression in the mouse ventricle. Al-
though IKACh has been recorded from human and ferret
ventricular myocytes (6,7), there is little published data
demonstrating the expression of GIRK1 or GIRK4 protein
or messenger RNA (mRNA) in the adult mammalian
ventricle. Given the significant difference observed in the
ventricular effective refractory period between the two ge-
notypes, we speculated that IKACh is present in the mouse
ventricle. To test this hypothesis, we used PCR to attempt
to amplify GIRK1- and GIRK4-specific fragments from
reverse-transcribed samples of total RNA from the mouse
ventricle. Both GIRK1 and GIRK4 were detected in the
samples of the mouse ventricle (Fig. 3). Detection of
GIRK1 and GIRK4 mRNA in the ventricle was not due to
contamination of the ventricular RNA samples by atrial
RNA, because mRNA encoding MLC-2a could not be
detected in the ventricular RNA samples. Myosin light
chain-2a is expressed in atrial but not ventricular myocytes
(19).
DISCUSSION
Acetylcholine is released from the vagus nerve of the
parasympathetic system and opposes many of the actions of
the sympathetic nervous system. It does so by activation of
the muscarinic type 2 receptor, which is coupled to the Gi G
protein heterotrimer. Gai inhibits Ga’s stimulation of
adenylyl cyclase and, in turn, its generation of protein kinase
A by the beta-adrenergic receptor. On the basis of data
primarily from the guinea pig, rabbit and rat, protein kinase
A phosphorylates a wealth of proteins in cardiac myocytes.
Most importantly, from the perspective of this study,
protein kinase A phosphorylates and increases the activity of
ion channels that speed pacemaker depolarization (If;
HCN), increase calcium entry (ICaL; a1C) and shorten the
action potential through one or more of the delayed rectifier
K1 currents (IKr; HERG, IKs; a heteromultimer of minK
and KvLQT1, and IKur; Kv1.5). It also slows pacemaker
depolarization directly by release of Gbg, which binds and
directly activates IKACh. Thus, the variety of changes noted
in the electrophysiologic variables measured in Table 1
reflect the large number of actions of acetylcholine and the
degree of beta-adrenergic stimulation under the recording
conditions (3).
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In this study, we have demonstrated that activation of
IKACh using a cholinergic agonist, such as carbachol, pre-
disposes the mouse atria to fibrillation. A lack of IKACh
prevented initiation of AF, but did not alter AV nodal
function significantly. A lack of IKACh had a favorable effect
on the ventricles by prolonging the effective refractory
Figure 1. (A) Induction of sustained atrial tachycardia in wild-type mouse after carbachol administration. Three atrial extrastimuli are delivered following
a basic drive train of 150 ms. (B) Sustained atrial fibrillation, with irregular atrial cycle lengths and variable ventricular response. IECG 5 intracardiac
electrogram; mV 5 millivolts; RA 5 right atrial; RV 5 right ventricular.
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period. These findings might have important therapeutic
implications.
IKACh involvement in AF. Several studies in larger mam-
mals have demonstrated that increased vagal tone, or aden-
osine administration, can promote the genesis of AF
(1,20,21). Vagal denervation of the atria prevented induc-
tion of AF and eliminated heart rate variability and barore-
flex sensitivity in dogs (1,2). Our findings in mice are
consistent with these studies. We demonstrated that sus-
tained AF could be induced in mice using programmed
stimulation after administration of cholinergic agonists,
such as carbachol. Furthermore, we showed that activation
of IKACh is essential for the profibrillatory action of carba-
chol, because the absence of IKACh uniformly prevented
initiation of AF. Activation of IKACh in response to vagal
stimulation may decrease the threshold to AF by decreasing
the atrial refractory period. Shortening of the atrial refrac-
tory period in response to cholinergic and adenosinergic
agonists has been previously demonstrated (20,22,23).
It is possible that AF in humans results from heteroge-
neous hyperactivity of IKACh. What could cause such
heterogeneous hyperactivity of IKACh? One possibility is
heterogeneous sympathetic denervation in the atria. Phenol
was used to cause heterogeneous sympathetic denervation in
the atria, and sites with sympathetic denervation had sig-
nificantly shorter effective refractory periods than sites
without denervation (24). Our study supports the hypoth-
esis that areas with IKACh hyperactivity would have shorter
effective refractory periods. Such anisotropic distribution of
refractory periods in the atrium could lead to AF.
IKACh involvement in mouse ventricular function. Ven-
tricular effective refractory periods were longer in KO mice
than in WT mice. Our observations suggest that IKACh
plays a significant role in the electrophysiologic properties of
the mouse ventricular myocardium. Consistent with this
functional observation, we detected both GIRK1 and
GIRK4 mRNAs in samples of total RNA from the adult
mouse ventricle, although at reduced levels compared with
those in the atria (data not shown). The expression of GIRK
subunits in the ventricle may be age- and species-
dependent. GIRK1 was not detected in RNA from adult rat
and guinea pig ventricles by Northern blot analysis, and
GIRK1 and GIRK4 proteins were not detected in adult
bovine ventricles by Western blot analysis (8,10). However,
using in situ hybridization, GIRK1 and GIRK4 have been
found to be expressed at comparable levels in the atria and
ventricles in late-stage rat embryos (25). Shortening of
action potential duration and stimulation of IKACh conduc-
tance in response to acetylcholine have been reported in
ventricular myocytes from humans, ferrets and frogs, but not
in ventricular myocytes from guinea pigs or chicks (6,26,27).
Prolongation of the ventricular refractory period is gen-
erally considered to be antiarrhythmic. Consistent with this
finding, there was no inducible ventricular tachyarrhythmia
with programmed ventricular stimulation in KO mice. This
is consistent with our previous study, which did not find any
spontaneous ventricular tachyarrhythmias during pro-
longed, continuous ECG monitoring of the KO mice.
Furthermore, there was no obvious difference in the fre-
quency of ectopic beats between the KO and WT mice. In
short, a lack of IKACh correlates with prolongation of the
ventricular effective refractory period and does not predis-
pose mice to ventricular arrhythmias.
Heightened vagal tone has been shown to have an
Table 1. Cardiac Electrophysiologic Variables of Wild-Type and IKACh-Deficient Mice Before and After Carbachol Administration
Variable
Wild-Type Mice IKACh-Deficient Mice
2CCh 1CCh D 2CCh 1CCh D
Atrium
Inducible fibrillation 0/14 10/14 (71%) 0/11 0/11*
Ventricle
ERP, 150 ms 48 6 12 58 6 13 11 6 7 68 6 11* 76 6 15† 8 6 10
Sinus node
Sinus cycle length 293 6 38 334 6 70 41 6 52 239 6 35† 265 6 41† 25 6 19
SNRT, 200 ms 275 6 90 438 6 160 164 6 97 243 6 69 328 6 106 83 6 77‡§
SNRT/SCL, 200 ms (%) 115 6 17 129 6 16 14 6 16 104 6 15 114 6 13‡ 11 6 14
SNRT, 150 ms 300 6 68 406 6 92 107 6 68 239 6 35 297 6 56‡ 35 6 41‡§
SNRT/SCL, 150 ms (%) 132 6 13 137 6 13 5 6 16 122 6 11 120 6 12‡ 2 6 6
AV node
AV interval 50 6 8 56 6 9 6 6 5 49 6 4 50 6 4 2 6 4‡§
AV Wenckebach 145 6 21 177 6 49 31 6 32 151 6 13 160 6 18 10 6 19§
AV 2:1 block 120 6 18 153 6 48 33 6 33 117 6 9 128 6 23 10 6 23§
AV ERP, 200 ms 93 6 18 134 6 46 43 6 38 98 6 16 122 6 23 23 6 29
AV ERP, 150 ms 106 6 20 106 6 20 15 6 16 109 6 12 107 6 10 8 6 4
VA Wenckebach 178 6 48 200 6 81 50 6 48 186 6 41 243 6 60 30 6 62
VA 2:1 block 144 6 51 144 6 21 19 6 14 129 6 33 153 6 38 15 6 22
*p , 0.001; †p , 0.01; ‡p , 0.05; §Indicates variable with an interaction effect. Statistical analysis was performed using two-way analysis of variance. Data are presented as the
number (%) of patients or the mean value 6 SD. All times are given in milliseconds.
AV 5 atrioventricular; CCh 5 carbachol; ERP 5 effective refractory period: 200 ms and 150 ms refer to the cycle lengths of the pacing protocols; SCL 5 sinus cycle length;
SNRT 5 sinus node recovery time; VA 5 ventriculo-atrial; D refers to the difference of the change in the variable before and after carbachol administration; 2CCh, 1CCh
and D columns of the IKACh-deficient mice refer to differences in these variables between the genotypes.
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antifibrillatory effect on the ventricles (28,29), and impaired
parasympathetic activity has been associated with an in-
creased risk of sudden death in both experimental and
clinical studies (29–35). Our finding that mice lacking
IKACh were not at an increased risk of ventricular fibrillation
suggests that alterations in parasympathetic activity are
Figure 2. Sinus node recovery times in wild-type (A) and IKACh-deficient (B) mice after pacing for 30 s at a cycle length of 150 ms. (A) The sinus node
recovery times were 315 ms at baseline and 505 ms after carbachol administration. (B) The sinus node recovery times were 255 ms at baseline and 300 ms
after carbachol. Pre-CCH 5 before administration of carbachol; Post-CCH 5 after administration of carbachol; RA IECG 5 right atrial intracardiac
electrogram; RV IECG 5 right ventricular intracardiac electrogram.
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unlikely to affect susceptibility to ventricular fibrillation
through IKACh.
IKACh involvement in sinus node function. Mice lacking
IKACh exhibited significantly shorter sinus cycle lengths
than did WT mice treated with carbachol. This is consistent
with findings from our previous study, which demonstrated
that after vagal stimulation or administration of the aden-
osine receptor agonist, GIRK4 KO mice had significantly
shorter sinus cycle lengths than did WT mice (15). On the
basis of these findings, we argued that IKACh mediates a
substantial portion of the heart rate decrease occurring after
vagal stimulation or adenosine administration.
In the present study, we found that KO mice have faster
heart rates than do WT mice at baseline, whereas in our
previous study, we found no significant difference in the
resting heart rate between WT and KO mice (15). This
discrepancy is likely due to the different conditions under
which the experiments were performed. Mice in the first
study were implanted with 8-g radiotransmitters, and heart
rate was recorded while the animals were conscious and
mobile. The presence of the transmitter may have triggered
sympathetic stimulation and negated a difference in rest
heart rate between the GIRK4 KO and WT mice. Indeed,
other groups using the implantable transmitters have re-
ported elevated rest heart rates (36,37). In the present study,
heart activity was recorded under general anesthesia. The
anesthesia likely ameliorated some of the sympathetic ef-
fects, accentuating a small difference in the mean heart rate.
We also observed a difference between WT and KO mice
in the time to recovery of sinus node function after rapid
atrial pacing in the presence of carbachol. In mice lacking
IKACh, the sinus node recovered faster than that in WT
mice. The inhibitory effect of IKACh on myocyte depolar-
ization may delay the spontaneous firing of sinus node cells
after a period of rapid pacing.
Specific IKACh antagonist as a possible antiarrhythmic
agent. It will be interesting to see whether specific IKACh
antagonists, if developed, will be useful in the treatment of
AF. Such a drug is likely to have favorable antiarrhythmic
effects in the ventricles, because a lack of IKACh caused
prolongation of the ventricular effective refractory period in
the GIRK4 KO mice. Specific IKACh antagonists are un-
likely to have significant effects on the AV node, as shown
by the lack of change in the AV nodal function in the KO
mice. However, specific IKACh antagonists might result in
faster rest heart rates because of the effect on sinus node
function. Torsade de pointes has been reported in humans
with potassium channel blockers, such as sotalol (38) and
dofetilide (39). Specific IKACh antagonists also need to be
evaluated in humans for a tendency to induce torsade de
pointes.
Study limitations. The data included this study are from
observations made in anesthetized mice and may not rep-
resent the physiologic situation in conscious humans. The
rate of atrial tachycardia induced in mice is much faster than
that in humans. This is likely due to the shorter action
potential duration and effective refractory period in mice
compared with humans.
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